IDEXX Laboratories, Inc. - Q1 2009 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for IDEXX Laboratories, Inc., covering the three-month period ended March 31, 2009. IDEXX operates primarily through three reportable segments: Companion Animal Group (CAG), Water quality products, and Production Animal Segment (PAS). The company also maintains smaller segments for Dairy and human medical diagnostics (OPTI Medical), reported under "Other."
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $236.5 million | $249.1 million |
| Gross Profit | $124.4 million (52.6% margin) | $129.8 million (52.1% margin) |
| Net Income | $26.1 million | $27.6 million |
| Diluted EPS | $0.43 | $0.43 |
| Operating Cash Flow | $12.6 million | ($2.8 million) |
| Cash and Equivalents | $86.3 million | $60.2 million |
| Short-term Debt | $165.5 million | $150.6 million |
| Working Capital | $75.6 million | $60.6 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5.1% year-over-year. This was driven by a 4.5% decline in the CAG segment, a 5.7% decline in Water, and a 13.7% decline in PAS. The "Other" segment saw a 4.1% increase.
- Currency Impact: A strengthening U.S. dollar negatively impacted reported revenue growth by approximately 2.6% across the company. Approximately 23% of revenue is derived from U.S. exports.
- Pharmaceutical Divestiture: Pharmaceutical product revenue dropped 98.4% to $54,000 following the sale of substantial pharmaceutical assets in late 2008. This divestiture also reduced operating expenses.
- Operating Expenses: Total operating expenses decreased 5.6% to $86.0 million, aided by the pharmaceutical transaction and favorable currency impacts on foreign expenses.
- Effective Tax Rate: The effective tax rate increased to 31.5% from 27.9% in the prior year. The prior year benefited from a non-recurring $1.5 million reduction in international deferred tax liabilities.
Outlook, Risks, and Management Commentary
- Economic Headwinds: Management notes that Q1 2009 results were negatively impacted by economic conditions, including fewer patient visits to veterinary clinics for routine care and cautious capital spending by veterinarians. Non-regulatory water testing volumes also declined due to reduced new home construction.
- Capital Allocation: The company repurchased $15.0 million of its common stock during the quarter. Capital expenditures were $9.1 million, with a full-year 2009 plan of approximately $55 million, largely for headquarters renovation.
- Liquidity: The company maintains $34.5 million in remaining borrowing availability under its revolving credit facility. Management believes current cash and credit facilities are sufficient for operations and strategic growth.
- Risks: Key risks include the potential for further economic deterioration affecting pet owner spending, continued volatility in foreign exchange rates, and the expiration of a key patent for feline immunodeficiency virus tests in June 2009.
Investor Verification Checklist
- Verify the sustainability of the 52.6% gross margin given the shift in product mix and the exit from the pharmaceutical business.
- Monitor the impact of the strengthening U.S. dollar on international margins, as 38% of revenue comes from outside the U.S.
- Assess the trajectory of veterinary patient visit volumes as a leading indicator for CAG revenue recovery.
- Review the status of the Cyntegra, Inc. antitrust appeal, with a decision expected in Q2 2009.
- Confirm the timeline and impact of the June 2009 patent expiration for SNAP FIV/FeLV tests.